| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_76ba102ea9c02b6633d64bf09c5b89a4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate |
2000-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_166a19241612195c9131f39a1d97378b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3713b4fb3fb484f23391e8d1027bd04 |
| publicationDate |
2002-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1212364-A1 |
| titleOfInvention |
MATERIALS AND METHODS FOR INHIBITION OF IgE PRODUCTION |
| abstract |
The subject invention concerns novel methods and materials for treating patients afflicted with allergic conditions, such as allergic rhinitis, atopic dermatitis, bronchial asthma and food allergy. The method of the subject invention comprises administering interferon tau (IFNτ) or a chimeric IFN (ovine IFNτ (1-27)/human IFNαD (28-166)) to a person afflicted with an allergic condition. When administered, IFNτ and chimeric IFN suppress the production of IgE antibodies without toxic side effects. The subject invention also concerns chimeric ovine/human IFNs which can be used in the methods of the invention. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8481575-B2 |
| priorityDate |
1999-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |